T1	Participants 94 146	chemotherapy in intermediate-stage Hodgkin's disease
T2	Participants 243 394	chemotherapy in nonbulky involved field (IF/BF) and noninvolved extended-field (EF/IF) sites in patients with intermediate-stage Hodgkin's disease (HD)
T3	Participants 418 506	HD patients in stage I to IIIA with a large mediastinal mass, E stage, or massive spleen
T4	Participants 803 974	46 patients who responded to chemotherapy were randomized to receive 20 Gy (70 patients) or 40 Gy (76 patients) of EF irradiation in all fields outside bulky disease sites
T5	Participants 976 1070	A cohort of 111 patients who fulfilled the same inclusion criteria in the subsequent trial HD5
T6	Participants 1786 1848	modern polychemotherapy in patients with intermediate-stage HD
T7	Participants 1881 1909	patients destined to relapse
